Glenmark Pharmaceuticals announced the FDA has approved Ryaltris, a fixed-dose (metered) combination nasal spray for the treatment of symptoms of Seasonal Allergic Rhinitis in adults…
Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite. Dr. Ron Brown – Opinion Editorial…
Spero Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product…
Kiniksa Pharmaceuticals announced results from the Phase 3 portion of the Phase 2/3 trial of mavrilimumab in COVID-19-related acute respiratory syndrome (ARDS). The trial was…
Pluristem announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLXPAD cells for the treatment…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
